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Infections due to Aspergillus species cause significant morbidity and mortality. Most are attributed
to Aspergillus fumigatus, followed by Aspergillus flavus and Aspergillus terreus. Aspergillus niger
is a mould that is rarely reported as a cause of pneumonia. A 72-year-old female with chronic
obstructive pulmonary disease and temporal arteritis being treated with steroids long term
presented with haemoptysis and pleuritic chest pain. Chest radiography revealed areas of
heterogeneous consolidation with cavitation in the right upper lobe of the lung. Induced bacterial
sputum cultures, and acid-fast smears and cultures were negative. Fungal sputum cultures grew
A. niger. The patient clinically improved on a combination therapy of empiric antibacterials and
voriconazole, followed by voriconazole monotherapy. After 4 weeks of voriconazole therapy,
however, repeat chest computed tomography scanning showed a significant progression of the
infection and near-complete necrosis of the right upper lobe of the lung. Serum voriconazole
levels were low–normal (1.0 mgm l
”1, normal range for the assay 0.5–6.0 mgm l
”1). A. niger was
again recovered from bronchoalveolar lavage specimens. A right upper lobectomy was performed,
and lung tissue cultures grew A. niger. Furthermore, the lung histopathology showed acute and
organizing pneumonia, fungal hyphae and oxalate crystallosis, confirming the diagnosis of invasive
A. niger infection. A. niger, unlike A. fumigatus and A. flavus, is less commonly considered a cause
of invasive aspergillosis (IA). The finding of calcium oxalate crystals in histopathology specimens is
classic for A. niger infection and can be helpful in making a diagnosis even in the absence of
conidia. Therapeutic drug monitoring may be useful in optimizing the treatment of IA given the
wide variations in the oral bioavailability of voriconazole.
Introduction
Aspergillus niger is a mould that is rarely reported as a cause
of pneumonia. Here we report a case of necrotizing A. niger
fungal pneumonia that did not respond to voriconazole in
a patient on long-term steroid treatment.
Case report
A 72-year-old woman presented with 3 weeks of a non-
productive cough and pleuritic chest pain. Her history was
notable for stage II chronic obstructive pulmonary disease
(COPD), not requiring systemic steroids or home oxygen
therapy, and a recent diagnosis of biopsy-proven temporal
arteritis. The latter was diagnosed 9 months previously and
she had been on tapering dose of dexamethasone (from 9
to 2.5 mg on presentation). She had seen her primary care
physician 2 weeks prior to presentation and was given a
course of moxifloxacin followed by azithromycin for
community-acquired pneumonia, but her symptoms
persisted.
The patient was afebrile with an oxygen saturation of 96%
on 2 l oxygen min
21 via nasal canula and a respiratory rate
of 18 breaths min
21. A pulmonary examination showed a
prolonged expiratory phase with crackles in the right upper
hemithorax. Laboratory results were notable for a leuko-
cytosis of 2.11610
10 leukocytes l
21. A chest radiograph
showed a right upper lobe heterogeneous opacity. She was
started on antibiotics for health-care-associated pneu-
monia and placed in special respiratory isolation given an
initial concern for tuberculosis. A chest computed
Abbreviations: COPD, chronic obstructive pulmonary disease; CT,
computed tomography; IA, invasive aspergillosis; IPA, invasive pulmonary
aspergillosis.
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tion in the right upper lobe with cavitation (Fig. 1).
Voriconazole was started empirically for fungal infection
given the cavitation seen on the CT scan and the patient’s
immunocompromised status. A bacterial sputum culture
showed oropharyngeal flora and an unidentified mould;
sputum fungal culture was sent for testing and grew A.
niger. Three acid-fast bacilli smears and cultures were
negative. Bronchoscopy found diffusely erythematous and
friable mucosa, blood and debris present in the right upper
lobe of the lungs; biopsies for histopathology were not
done due to oxygen desaturations during the procedure.
Cytology testing and cultures from the bronchoalveolar
lavage were negative.
Surgical resection of the cavitary lesion was considered, but
the patient refused surgical intervention. Her symptoms
improved and her leukocytosis resolved with empiric
antifungal and antibacterial therapy. The patient met
criteria for probable invasive Aspergillus infection (De
Pauw et al., 2008) and after consultation with the Thoracic
Surgery, Infectious Disease, and Pulmonary teams of the
Duke University Medical Center, the decision was made to
treat her with 200 mg voriconazole orally twice daily.
Follow-up in the Infectious Disease Clinic (Duke
University Medical Center) and a repeat CT scan was
planned for 4 weeks later.
On her visit to the Infectious Disease Clinic 1 month later,
the patient reported feeling better, with decreased cough.
However, a CT scan demonstrated increasing cavitation
and progression of the disease despite therapy with
voriconazole. Serum voriconazole levels were low–normal
[1.0 mgm l
21 (normal range for assay 0.5–6.0 mgm l
21)].
Bronchoscopy was again performed, with repeat cultures
persistently growing A. niger. Bacterial cultures remained
negative. With progression of the disease shown by
radiography and persistently positive cultures, surgical
intervention was reconsidered. The patient subsequently
underwent right upper lobectomy. Surgical cultures grew
A. niger. Pathology revealed acute and organizing pneu-
monia, stains consistent with fungal hyphae and oxalate
crystallosis (Fig. 2), thus fulfilling the criteria for the
diagnosis of proven invasive A. niger infection (De Pauw
et al., 2008). The patient had an uncomplicated post-
operative course, and was discharged with pulmonary
rehabilitation and continued voriconazole therapy.
Discussion
Infections due to Aspergillus species result in significant
morbidity and mortality. Most infections are attributed to
Aspergillus fumigatus (Table 1), followed by Aspergillus
flavus and Aspergillus terreus. A. niger is less commonly
reported as a cause of invasive disease. A. niger has been
associated with otomycosis (Araiza et al., 2006), cutaneous
infections (Loudon et al., 1996) and pulmonary disease.
There are few reports of A. niger causing pneumonia. In
three separate case reports, A. niger pulmonary infection
was fatal; one patient had been on long-term steroid
treatment for COPD (Wiggins et al., 1989), a second had a
history of asbestos exposure and tuberculosis (Nakagawa
et al., 1999) and a third had a history of Mycobacterium
avium complex causing cavitary disease (Kimmerling et al.,
1992). All had evidence of heavy calcium oxalate
deposition on pathological examination. A review of
COPD patients with invasive pulmonary aspergillosis
(IPA) found 3.6% of cases were due to A. niger (Bulpa
et al., 2007). In a case series of eight patients with invasive
A. niger infection and haematological malignancies, three
were on high-dose steroids, and seven were neutropenic.
Fig. 1. Chest CT scan showing heterogeneous consolidation in
the right upper lobe of the lungs with cavitation.
Fig. 2. Surgical pathology ofspecimens from right upper lobectomy
of the lung, showing acute and organizing pneumonia and oxalate
crystallosis consistent with A. niger infection. Bars, 25 mm.
A. niger causing necrotizing pneumonia
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(Fianchi et al., 2004).
The diagnostic dilemma presented in this case was the
determination of the aetiology of the patient’s cavitary lung
disease. The differential diagnosis of cavitary lung lesions is
broad. Our patient was at risk for fungal infections,
mycobacterial infections including Mycobacterium tuber-
culosis and other bacterial pathogens, given her long-term
steroid use. The cause of our patient’s necrotizing
pneumonia was initially attributed to A. niger, as this was
the only pathogen recovered from sputum samples.
However, it can be difficult to distinguish between
colonization and infection when Aspergillus is found in
the lungs. Identifying Aspergillus in the lower respiratory
tract was associated with invasive disease in a study of
patients with haematological malignancies or those under-
going haematopoietic stem cell transplantation (Perfect
et al., 2001). However, among lung transplant recipients,
recovery of Aspergillus rarely resulted in progression to
overt infection (Mehrad et al., 2001). A review of COPD
patients with IPA highlights the need to distinguish
between colonization and infection, and suggests a
diagnostic algorithm for these patients. Sputum cultures
alone may not be helpful; out of 56 COPD patients with
IPA, only 12 (21.4%) had cultures positive for Aspergillus
(Bulpa et al., 2007). Thus, serological tests (such as the
galactomannan antigen assay) and radiography tests (with
‘halo sign’ and ‘air crescent sign’ on CT being highly
suggestive of IPA) must often be combined with micro-
biological/histological data to establish a diagnosis of true
infection. Conclusive culture data or histological evidence
of IPA may necessitate bronchoscopy or lung biopsy.
A key feature in the diagnosis of A. niger infection is the
presence of calcium oxalate crystals on pathological
examination. Oxalic acid precipitates and forms crystals
when produced via a fermentation process by A. niger. The
association of calcium oxalate crystals with A. niger
infection has been repeatedly demonstrated, and it has
been suggested that even in the absence of visualized
conidia, the presence of these crystals may indicate A. niger
infection (Procop & Johnston, 1997). Both calcium oxalate
crystals and numerous conidia were seen in our patient’s
pathological specimens, pointing to A. niger as the
aetiological agent of our patient’s cavitary lung lesions.
Treatment of invasive aspergillosis (IA) has evolved; one
large, unblinded, randomized controlled trial of amphoter-
icin B versus voriconazole demonstrated improved 12 week
survival rates and decreased drug-related adverse events
with voriconazole (Herbrecht et al., 2002). Voriconazole is
thus considered the drug of choice for IA (Walsh et al.,
2008). When our patient demonstrated significant pro-
gression of cavitation on her chest CT despite therapy with
voriconazole, one possible explanation was azole resistance.
In the USA, however, the resistance of Aspergillus to azoles
is uncommon (Baddley et al., 2009), and therefore
susceptibility testing of our patient’s isolate was not
performed. Another possible explanation for progressive
disease was that subtherapeutic voriconazole levels were
contributing to failure of therapy.
The role of therapeutic drug monitoring for voriconazole is
controversial. Voriconazole exhibits nonlinear
pharmacokinetics; it has been shown that there is great
variability in the serum level among healthy hosts. The
wide variation in serum levels is due to differences in the
ability of hosts to metabolize voriconazole through the
CYP450 enzyme (Bochud et al., 2008); specifically,
polymorphisms in CYP2C19 have delineated ‘poor’ and
‘extensive’ metabolizers of voriconazole (Desta et al.,
2002). Not only do levels vary, but the goal serum
concentration for voriconazole is unknown. In one
retrospective review of voriconazole level monitoring, a
pharmacokinetic-pharmacodynamic breakpoint was
observed around a concentration of 2.05 mgm l
21. Those
with serum levels above this level responded favourably to
Table 1. Characteristics of A. niger versus A. fumigatus
A. fumigatus is a much more common cause of IPA compared to A. niger; this may be due to their differences in morphology.
A. fumigatus A. niger
Frequency in invasive infection 66–90% (Patterson et al., 2000). 5% (Patterson et al., 2000).
Voriconazole MIC90 0.25–2.0 mgm l
21 (Johnson & Kauffman, 2003). 0.5–4.0 mgm l
21 (Johnson & Kauffman, 2003).
Size 2–3.5 mm; small size allows entry into lower
respiratory tract and more invasive pulmonary
disease (Sutton et al., 1998).
6–7 mm; large size allows easy uptake by host
mucociliary system and more upper
respiratory infections: otitis,
tracheobronchitis (Xavier et al., 2008).
Temperature for growth Thermophilic species (growth at 40 uC and
above) allowing easier growth in human
lungs (Araujo & Rodrigues, 2004).
Less thermotolerant, ideal temperature for
growth is 30–34 uC, making germination
difficult in human body temperature of at
least 37 uC (Xavier et al., 2008).
pH for optimal growth Prefers acidic environment but can tolerate
growth through a broad range of pH, including
slightly alkaline pH (Araujo & Rodrigues, 2004).
Acidophilic nature with maximal germination
at pH of 4.5, limiting its growth; low pH allows
oxalic acid production (Xavier et al., 2008).
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2.05 mgm l
21 had progression of disease (Smith et al., 2006).
Our patient’sserum voriconazolelevel was1.0 mgm l
21,s oi t
is possible that despite falling within the normal range for
theassay (0.5–6.0 mgm l
21),the dose wasnottrulyadequate.
Guidelines on the treatment and management of IA
recommend considering therapeutic drug monitoring in
patients who have progressive infection despite presumed
adequate dosing (Walsh et al., 2008). The protocol in the
initial study of voriconazole included an intravenous
loading dose (Herbrecht et al., 2002); as a result, current
recommendations are for a loading dose to be given
parenterally if possible, and if not, an oral loading dose is
recommended (Walsh et al., 2008). Our patient did not
receive a loading dose, and this may have contributed to
inadequate serum levels. Ultimately, our patient required
surgical intervention. IA is an uncommon surgical disease;
most surgical series are small and composed of patients with
either haematological malignancies or transplants (Baron
et al., 1998; Danner et al., 2008; Robinson et al., 1995;
Salerno et al., 1998). In this case, the major indications for
surgery were the radiographical evidence of disease progres-
sion despite appropriate antifungal therapy and the
continued need for immunosuppression. Regardless of
underlying diagnoses, other indications for surgery in
patients with IPA include haemoptysis, a critical anatomical
location of cavitary lesions, and the presence of focal (and
therefore resectable) lesions (Danner et al., 2008).
In conclusion, although IA is a well-recognized clinical
entity, invasive disease caused by A. niger is less common
when compared to A. fumigatus and other Aspergillus
species, and diagnosis can be complicated by the need to
distinguish colonization from infection. This case demon-
strates thepotentially aggressive nature of A. niger, the utility
of calcium oxalosis in histopathological examinations, and
the importance of monitoring serum voriconazole concen-
trations, especially in the setting of progressive disease.
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